Frontlight ResearchEarly access
WithdrawnPhase 1/2
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Key facts
- Who runs it
- Context Therapeutics Inc.
- Where
- Nashville, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- Jun 2023
- Ended
- Dec 2023
- Type of study
- Interventional
- Treatments tested
- Elacestrant
- Onapristone
- Record updated
- 22 April 2025
- Why it stopped
- Change in corporate strategy.
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patient is currently enrolled in the ELONA clinical study (ONA-XR-103) and receiving onapristone or elacestrant, either alone or in combination
- Patient is currently benefiting from the treatment in the ELONA clinical study, as determined by the investigator
- Patient currently has no evidence of progressive disease, as determined by the investigator
Who cannot take part
- Pregnant or nursing (lactating) women
- Female patients of childbearing potential (e.g., are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective contraception, throughout the study and for up to 30 days after stopping study treatment
Where in United States
- Sarah Cannon Research InstituteNashville, United States
About the trial
What the trial wants to find out
This is a rollover study for patients enrolled in the discontinued ELONA clinical trial (ONA-XR-103) with the primary objective to characterize the safety of elacestrant in combination with onapristone either alone or in combination.
The group in the trial
- Elacestrant / OnapristoneTreatment being tested
Elacestrant and Onapristone combination
Treatment: Elacestrant and Onapristone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer
- Record updated
- 22 April 2025